INTRODUCTION
Genetic tools provide a powerful approach to establishing causal relationships between the activity of specific neuronal circuits and behavior (reviewed in Callaway [2005] , Deisseroth et al. [2006] , Schafer [2005] ). Recently, various methods have been developed to reversibly silence neuronal activity with genetically encoded effector molecules in mammalian systems. Several (but not all) of these systems have also been employed in Drosophila (Thum et al., 2006) . Two fundamentally different approaches have been undertaken: the first targets neurotransmitter release and the second neuronal excitability. Within these two categories, reversibility has been achieved using either transcriptional control or protein activation/inactivation. While significant progress has been made, each of these methods has different limitations, and many have not been tested for their ability to perturb behavior in freely moving animals.
Two methods for inhibiting neurotransmitter release have been used in mice. Tetanus toxin light chain (TNT) was used to cleave VAMP2/Synaptobrevin, a synaptic vesicle protein (Yamamoto et al., 2003; Yu et al., 2004) . Regulation is achieved by inducible transcription, and recovery occurs when the cell resynthesizes VAMP2. While this system can influence behavior (Yamamoto et al., 2003) , the transcriptional induction has a relatively slow onset of 14 days. More recently, small molecule-induced crosslinking of genetically modified forms of VAMP2 (''MIST'') was shown to inhibit neurotransmission in vitro and also to influence behavior in vivo, when expressed in cerebellar Purkinje cells (Karpova et al., 2005) . This is a potentially powerful method; however, the crosslinking agent was delivered intracerebroventricularly (ICV) and has not yet been tested using systemic administration. More importantly, because this approach does not directly suppress neuronal excitability, the postsynaptic targets of the manipulated neurons must already be known in order to validate silencing electrophysiologically (Karpova et al., 2005; Yu et al., 2004) .
Several genetically encoded suppressors of membrane excitability have been developed. These methods permit validation of silencing in the targeted neurons, without prior knowledge of their postsynaptic targets. The strongly rectifying potassium channel Kir2.1 silences neurons (Johns et al., 1999; Nitabach et al., 2002; Yu et al., 2004) and, unlike weakly rectifying potassium channels (Nadeau et al., 2000) , does not kill cells due to potassium leak. Because these channels are constitutively active, however, reversibility must be achieved through transcriptional control. Similarly, electrical silencing has been achieved by expression of membrane-tethered toxins that bind sodium channels or nicotinic receptors (Ibanez-Tallon et al., 2004) , but reversibility also requires inducible transcriptional regulation. Another approach employs expression of a G protein-coupled receptor (GPCR) for the Drosophila neuropeptide allatostatin (Lechner et al., 2002) . This elegant method rapidly and reversibly silences neuronal spiking activity in vivo Tan et al., 2006) . However, because the ligand is a neuropeptide, it does not cross the blood-brain barrier (BBB) and therefore must be delivered ICV, an inconvenient method when many animals are required for behavioral experiments. None of these methods, moreover, has been validated in awake behaving mice. To date, therefore, no study has described a method that reversibly suppresses neuronal excitability, is gated by a ligand that crosses the BBB, and that demonstrably affects behavior in freely moving animals.
We previously described a method for regulated inhibition of neuronal excitability, employing coexpression of two subunits (a and b) that comprise a C. elegans glutamate-and ivermectin (IVM)-gated chloride channel (GluClab; Slimko et al., 2002) . This heteromeric channel prevents action potential firing by hyperpolarizing the membrane in a ligand-dependent manner. Coexpression of the two subunits in cultures of dissociated hippocampal neurons, followed by IVM application, effectively suppressed spiking . Subsequently, we codon-optimized GluClab for mammalian expression, reduced sensitivity to endogenous glutamate by site-directed mutagenesis, and incorporated fluorescent moieties to facilitate detection of expression (Li et al., 2002; Slimko and Lester, 2003) .
These in vitro studies left open the question of whether the GluCl/IVM system is efficacious in vivo. Ivermectin at veterinary doses has little or no effect on mouse behavior (Davis et al., 1999) , but it remained unclear whether (1) stable expression of GluClab could be achieved in vivo without neurotoxicity, (2) significant IVM-independent baseline silencing would occur due to local glutamate release, (3) IVM could cross the BBB at levels sufficiently high to activate GluClab without organismal toxicity, (4) GluCl/IVM activation would be reversible in vivo, and (5) GluCl/IVM-mediated neuronal silencing could be used to manipulate behavior in awake, freely moving animals.
Here, we present evidence that the GluClab channel can be activated by systemic administration of IVM in vivo, that GluCl/IVM-dependent silencing of striatal neurons can influence behavior without measurable neuronal or organismal toxicity, and that repeated cycles of silencing and recovery can be obtained within individual animals. This two-subunit system is well suited to ''intersectional'' strategies designed to increase the cellular specificity of silencing in transgenic animals.
RESULTS

Expression of GluCl Channel Subunits in the Striatum
To test whether the GluCl/IVM system can be used for in vivo silencing, we expressed independently each of the codon-optimized, FP-tagged subunits, called optGluCla-CFP and optGluClbY182F-YFP (Li et al., 2002; Slimko and Lester, 2003) , using an adenoassociated virus (AAV) vector ( Figure 1A ). Transcription was driven by a cytomegalovirus (CMV) early promoter, and a woodchuck hepatitis posttranscriptional regulatory element (WPRE) was inserted for additional enhancement of expression (Figure 1A) . Both constructs were commercially packaged and serotyped with the AAV2 capsid protein (Virapur, Inc.), yielding titers of 10 12 particles per ml. We refer to the viruses encoding the a and b subunit as AAV2-a and AAV2-b, respectively ( Figure 1A ). We injected a mixture of both viruses into several brain regions and found that the striatum allows for good virus spread ( Figure 1B ). Striatal injection of 2 ml of the virus suspension (approximately 2 3 10 9 particles) yielded infected volumes of 0.5 to 1.6 mm 3 . Immunolabeling with anti-GFP antibodies indicated that, as expected, GluClab is localized to membranes and is visible in neuronal projections ( Figure 1C ). Colabeling with NeuN, a neuronal nuclear marker, confirmed that nearly all infected cells are neurons ( Figure 1C ). Cell counts using confocal images of 20 mm sections indicated that, within the infected region, close to 80% of NeuN + cells were infected (79.6% ± 1.3%, mean ± SEM, n = 10 sections). IVM-dependent silencing occurs only if both a and b subunits of the heteromeric channel are expressed in the same cell. To assess the extent of coexpression, we visualized native CFP and YFP fluorescence using confocal microscopy. The majority of infected cells in the striatum coexpressed both subunits ( Figures 1H and 1I ). Control experiments using single-subunit infections confirmed the absence of artifactual bleed-through fluorescence (Figures 1D-1G ). While $50% of cells expressed both channels at comparable levels ( Figures 1H and 1I , white arrows), $50% expressed more strongly one or the other subunit ( Figures 1H and 1I , orange and red arrows). Nevertheless, all cells that showed a strong signal for one subunit also showed detectable expression of the other subunit.
IVM-Dependent Silencing by GluCl/IVM In Vivo
To assess whether neuronal silencing by GluCl/IVM can produce behavioral phenotypes in vivo, we sought a relatively simple system with a robust and reproducible behavioral response that is sensitive to perturbation of neuronal activity. The striatum plays an important role in relaying dopaminergic signaling from the substantia nigra to motor and sensory areas (Graybiel, 2005) . Unilateral disruption of nigrostriatal signaling has been extensively employed in animal models of movement disorders, such as Parkinson's disease (Willis and Kennedy, 2004) . Because such manipulations produce only subtle effects on spontaneous locomotor activity in rodents, a widely used assay employs systemic administration of amphetamine (AMP) to enhance locomotion (Ungerstedt, 1971) . In animals bearing unilateral damage to the striatum or the substantia nigra, AMP produces a relative enhancement of dopaminergic transmission in the contralateral (control) striatum, causing rotations toward the lesioned side, i.e., ipsilaterally (Schwarcz et al., 1979; Ungerstedt and Arbuthnott, 1970) .
We used a variation of this assay in order to test for behavioral effects of GluCl/IVM-mediated neuronal silencing (see Figure 2A ). Two microliters of virus suspension ($2 3 10 9 particles) was injected into one side of the striatum at the level of bregma. The suspension contained either AAV2-a or AAV2-b alone or a 1:1 mixture of both viruses (AVV2-a + AAV2-b). Between 14 and 30 days after virus injection, animals were injected intraperitoneally (i.p.) with IVM (10 mg/kg). In preliminary studies, control mice injected with this dosage of IVM showed no obvious impairment of spontaneous locomotor activity in an open field test or performance deficits in other locomotor-dependent behavioral tests, such as the rotarod assay (see Figure S1 in the Supplemental Data available with this article online).
To assess rotational behavior, mice were given a single intraperitoneal (i.p.) injection of AMP (5 mg/kg), and placed into a square open field box (55 3 55 cm). Locomotor trajectories (see examples in Figures 2F-2I ) were recorded on videotape and analyzed using Ethovision 3.0 software (Noldus, Inc.). The number of full 360 locomotor circles, performed without any change in direction, was counted during a 30 min period, beginning 10 min after AMP injection (Figure 2A ). Ipsilateral and contralateral rotations (relative to the side injected with virus) were scored as positive and negative, respectively. Because the animals were allowed to move freely during the test, we normalized for the total distance traveled during the 30 min scoring period; the parameter measured was thus the net number of rotations (ipsilateral plus contralateral) per 10 min. Wider circles, such as those exhibited by control mice when moving around the chamber perimeter, thus yield a lower score than smaller circles.
In mice injected with the mixed virus suspension encoding both subunits of GluCl and given IVM, administration of AMP 12 hr later ( Figure 2A ) promoted strong unilateral rotation activity, in the direction ipsilateral to the viral injection side (Figures 2B and 2I ; Movie S1). The median rotation score for (AAV2-a + AAV2-b)-injected animals was significantly higher than in animals injected with the a virus alone, the b virus alone, or no virus (sham injection; ANOVA followed by post hoc Kolmogorov-Smirnov test; Figures 2B and 2G ). There was no significant difference (p > 0.3) between the results for any of these three control groups ( Figure 2B ). Animals injected with (AAV2-a + AAV2-b) showed no AMP-induced rotations in the absence of IVM ( Figure 2H ). Thus, AMP-induced rotations require the expression of both GluCl subunits, as well as administration of IVM. Importantly, the fact that AMPsensitivity was achieved by i.p. injection of IVM indicates that the ligand can cross the BBB at levels sufficient to activate GluClab.
In preliminary time-course and dose-response experiments, we found that each group of (AAV2-a + AAV2-b)-injected mice contained some animals that appeared unresponsive to IVM. To distinguish whether this variation reflected the particular IVM dose or was time-point tested, or rather a general lack of IVM responsiveness, all animals from these experiments were retested at the end of the experiment using a uniform IVM dose. IVM at 10 mg/kg was administered 16 days after the original injection (when the initial response had decayed to baseline [ Table 1 ]), and AMP-induced rotation tested in all animals 12 hr later. The resulting scores (n = 56 animals) were plotted as a histogram ( Figure 2C ). The data clearly exhibited a bimodal distribution. One group of animals exhibited a weak but significant rotation phenotype ( Figures 2C and 2D , ''weak''; average = 2.3 ± 0.4 circles/10 min, n = 22) when compared with the control groups ( Figure 2D ; pooled average = 0.5 ± 0.2, n = 15, p < 0.001), while the second group exhibited a strong rotation phenotype (Figures 2C and 2D, ''strong''; average = 60.4 ± 1.7, n = 34) . Similar results were obtained comparing the total number of rotations during the 30 min period (ipsilateral circles > 0, contralateral circles < 0): control mice showed an average of 0.5 ± 4.6 circles (n = 15); animals with a weak phenotype, 22.9 ± 5.6 circles (n = 22); and animals with a strong phenotype, 251.2 ± 21.1 circles (n = 34). 
Neuron
GluCl/IVM-Dependent Silencing of Striatal Neurons
To determine whether there was a correlation between the strength of the rotation phenotype and the level of striatal GluClab expression, three animals were chosen randomly from each behavioral group (weak and strong) and the volume of the virally infected region in their brains determined by immunostaining for GFP and quantified using Stereo Investigator software (Microbrightfield, Inc.). There was a significant difference between the weak and strong groups in the volume of striatum expressing GluClab ( Figure 2E ; 0.5 ± 0.1 mm 3 versus 1.7 ± 0.1 mm 3 , respectively, p < 0.005). These data suggest that the nonresponsive animals have a lower extent of infection by (AAV2-a + AAV2-b), which is below a threshold necessary to elicit a strong behavioral phenotype.
IVM Inhibits Firing of Striatal Neurons in Slices Derived from GluClab-Expressing Animals
To determine whether the AMP-induced, GluCl/IVM-dependent rotation phenotype is associated with silencing of neurons in the striatum, we measured firing by wholecell patch clamp recording, in striatal slices taken from animals stereotaxically injected with an (AVV2-a + AAV2-b) virus suspension. Recordings were performed within an area of 750 mm around the presumptive injection site (2.2 mm lateral, 2.5 mm to 4 mm ventral to bregma). Signals were obtained from two types of neurons: medium spiny neurons (MSN, n = 12) and interneurons (IN, n = 20), which were distinguished by their differences in resting membrane potential (MSNs, À76 ± 3 mV; INs, À50 ± 2 mV; Jiang and North, 1991; Wilson, 1998) . The effect of bathapplied IVM was determined on spontaneous action potential firing (in the case of INs) or on firing evoked by injection of depolarizing current (20-180 pA) in the case of MSNs, whose baseline firing frequency was otherwise too low for systematic studies on IVM effects. When 20 nM IVM was applied to the slices from (AAV2-a + AAV2-b) injected animals, we observed three types of responses (Figures 3A-3C): (1) full inhibition of firing after 7 min of perfusion with IVM ( Figure 3A , 95% ± 2% inhibition of firing rate, n = 12); (2) partial inhibition after 15 min of perfusion with IVM ( Figure 3B , 56% ± 5% inhibition, n = 6); (3) no inhibition ( Figure 3C , n = 14). None of the neurons recorded in control slices from sham-injected animals showed any inhibition of firing after 15 min of IVM perfusion (data not shown, n = 6). There was no statistical difference in the proportion of MSNs and INs inhibited: 67% of MSN showed inhibition (8/12; five strong, three weak) and 50% of IN were inhibited (10/20, five strong, five weak).
Previous studies characterizing GluClab expressed in dissociated cultures of hippocampal neurons indicated that inhibition of neuronal activity is accompanied by an increase in membrane conductance and by hyperpolarization of the membrane potential , Li et al., 2002 , Slimko and Lester, 2003 , consistent with an IVM-gated chloride conductance. Similarly, in striatal slices obtained from (AAV2-a + AAV2-b)-infected mice, we observed a significant negative correlation (r = À0.62, p < 0.01) between the rate of spike firing after IVM perfusion, relative to baseline (''% pre-IVM''), and membrane conductance (G memb ; Figure 3D , left panel). A significant increase in average G memb was observed in neurons with full inhibition of firing (n = 5, p < 0.01) and partial inhibition of firing (n = 4, p < 0.05; Figure 3D , right panel). No change in G memb was observed in noninhibited neurons. Spike firing after IVM perfusion (relative to baseline) was also negatively correlated with membrane hyperpolarization ( Figure 3E , left panel; r = À0.81, n = 16, p < 0.0001). Both fully inhibited and partially inhibited neurons showed a significant IVM-dependent hyperpolarization (p < 0.01), while neurons showing no inhibition of firing, showed no hyperpolarization (p > 0.1; Figure 3E , right panel).
The expression of GluCla and b in virus-infected cells varies among individual neurons within the injected area. We sought to determine whether this variation in GluClab levels correlates with the variation in the inhibition of spiking by IVM. Prospective identification of GluClab-expressing neurons in striatal slices was challenging because of the high levels of autofluorescence and expression of GluClab in processes, rather than somata. Thus, we recorded from randomly selected cells in the infected area (one cell per slice) and filled the cell with a far red fluorescent dye (Alexa 647-dextran). After fixation of each 250 mm slice and resectioning at 30 mm, we were able to unequivocally identify six filled cells ( Figure 3F ). Quantitative spectral analysis of each identified cell showed a negative correlation between CFP and YFP fluorescence intensity and firing rate after IVM perfusion, relative to baseline (''% pre-IVM, '' Figures 3G and 3H) . Fully inhibited cells expressed CFP and YFP at levels near the median of the population and 15-fold lower than that of the most highly expressing cells ( Figure S2 ). The upper two rows show rotation scores at the indicated time points after 5 mg/kg and 10 mg/kg IVM injection. The data for 5 mg/kg IVM are plotted in Figure 4D . The third row shows p values unpaired t tests of statistical significance between 5 mg/kg and 10 mg/kg IVM injections. a Significant after Bonferroni correction. (H) YFP fluorescence is negatively correlated with firing rate after IVM, relative to baseline (r = À0.91, p < 0.005). CFP and YFP fluorescence intensity in each cell is normalized to the median intensity for 11 GluClab-expressing cells (see Figure S2 ).
We also tested for a correlation between the strength of the behavioral phenotype produced by IVM in vivo and the two types of firing inhibition (full and partial) observed in slice recordings. Recordings from striatal neurons were performed in slices from 13 (AAV2-a + AAV2-b)-injected animals, 8 of which showed a strong rotation phenotype (cf. Figure 2C) , and 5 of which showed a weak phenotype, as well as from three sham-injected animals, by a person blind to the behavioral phenotype. There was a clear correlation between the percentage of neurons showing full, partial, or no inhibition, and the strength of the behavioral phenotype ( Figure 3I ): slices from animals showing a strong rotation phenotype exhibited the greatest proportion of inhibited (full + partial) neurons ($70%), and a high percentage of such neurons were fully inhibited ($71%). In addition, the median firing rate after IVM perfusion was significantly lower in animals showing a strong rotation phenotype than in sham-injected animals or animals with a weak rotation phenotype ( Figure 3J ). Thus, the strength of the rotation phenotype is correlated with the percentage of neurons inhibited by IVM, as well as with the strength of inhibition. Taken together, the data indicate that mice exhibiting a strong behavioral phenotype (Figure 2C) show both a greater extent of infection by AAV2-GluClab ( Figure 2E ) and a greater extent of IVM-dependent spike suppression in vitro.
IVM Dosage Sensitivity of GluClab-Dependent Silencing In Vivo
We next investigated the minimum dose of IVM necessary to elicit a rotation phenotype, using the experimental design shown in Figure 4A . Two weeks after viral infection, GluClab-expressing animals were injected with AMP to confirm the lack of significant rotation in the absence of IVM ( Figure 4A , ''AMP''; Figure 4B , ''pretest''). GluClabexpressing mice were then injected 1 day later with a single dose of IVM ( Figure 4A , ''IVM''), using one of five different concentrations between 0 and 10 mg/kg (n = 4-5 animals per dose) and tested 12 hr later for AMP induced rotation ( Figure 4A , ''AMP''). ANOVA showed a significant interaction between pretest versus posttest and IVM concentration (p < 10 À6 ). Thus, we performed post hoc t tests between pretest and posttest for the individual IVM concentrations. There was no significant effect, relative to pretest, of IVM at doses %2.5 mg/kg (p > 0.05), while a significant increase in rotation was observed at 5 mg/kg IVM (p < 0.01, n = 5) and at 10 mg/kg (p < 0.005, n = 4; Figure 4B ). Although there was a trend toward a higher mean rotation score at 10 mg/kg IVM compared to 5 mg/kg ( Figure 4B ), this difference was not statistically significant (p > 0.2). To ensure that animals with similar sensitivities to IVM were compared in the dose-response experiment, 16 days following the AMP test (when the IVM effect has decayed; see Figure 4D ), all mice were reinjected with 10 mg/kg IVM and tested after 12 hr for AMP-induced rotation. Only data from animals exhibiting a ''strong'' phenotype in this retest ( Figure 2C ; >10 ipsilateral circles per 10 min) were included in the dose response study (10 of 31 animals were excluded by this criterion).
There was no statistically significant difference in rotation score between animals not excluded by this retest (p > 0.1, data not shown).
Kinetics of Onset and Decay of IVM Effect on Behavior
We next investigated the kinetics of the onset and decay of IVM-dependent, AMP-induced rotation. Eight independent groups of mice were injected with AAV2-a+ AAV2-b (n = 3-6 animals/group). Two weeks after virus injection, mice were pretested with AMP in order to establish baseline behavior ( Figure 4C , ''AMP/pretest''). One day later, all mice received 5 mg/kg IVM ( Figure 4C , ''IVM''). At different time points after the IVM injection, each group of mice was injected with AMP and scored for rotational behavior ( Figure 4C , ''scoring''). At this dose of IVM, the earliest time at which a statistically significant AMP-induced rotation was observed was at 12 hr post-IVM injection (p < 0.02; Figure 4D ). A maximal effect was achieved by 24 hr and persisted for 2 days. The AMP-induced rotation began to decline on day 3 ( Figure 4D ). The rotation scores at 4 and 5 days post-IVM injection were not significantly different from pretest controls, although a few animals showed detectable circling. By 14 days after the IVM injection, none of the animals showed a detectable AMPinduced rotation. To ensure that all animals used in the time-course experiment were capable of similar responses when tested with AMP at the same time interval after IVM injection, at day 16 all animals were reinjected with 10 mg/kg IVM and then tested 12 hr later for AMPinduced rotation. Only data from animals scoring at least 10 circles/10 min were included in the analysis (34 out of 56 animals). There was no statistical difference between the mean rotation scores for any groups not excluded by this retest (p > 0.05, data not shown). We also performed a similar time-course experiment with animals receiving 10 mg/kg IVM. In this case, a significant AMP-induced rotation response was observed as early as 6 hr post-IVM, with maximal levels achieved by 12 hr and maintained to day 3 (Table 1 ). The rate of onset for IVM at 10 mg/kg was significantly higher than that In theory, recovery could be due to temporal downregulation of the CMV promoter caused by silencing. However, there was no significant difference in the density of GluClab-expressing neurons at 24 hr after IVM injection, when silencing is maximal, versus 6 days after injection, when silencing had decayed (79.5% ± 2.1% GFP + /NeuN + neurons after 24 hr versus 82.3% ± 3.4% Table 1 for significance tests and data for 10 mg/kg IVM.
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GluCl/IVM-Dependent Silencing of Striatal Neurons GFP + /NeuN + neurons after 6 days; n = 10 sections/time point, p > 0.5).
Multiple Cycles of Striatal Silencing by IVM in GluClab-Expressing Mice
The foregoing data implied that the effects of IVM are reversible, when different animals are compared at different time points after injection. We next sought to determine whether multiple cycles of reversible inhibition could be obtained within the same animals. To this end, a single group of GluClab-expressing animals was repeatedly tested for AMP-induced rotation at multiple time points after an initial injection of IVM (10 mg/kg), followed by two additional IVM injections ( Figure 5A) . A small but significant rotation response to AMP could be detected at 4 hr after the first IVM injection (p < 0.05), with a maximal response being achieved by $24 hr and persisting for at least 3 days ( Figure 5B ). The IVM effect declined strongly between 3 and 6 days but did not decline further at 14 days. Upon a second administration of IVM, the rotation response was restored to maximal levels when the animals were tested with AMP 24 hr post-IVM injection ( Figure 5B ). After 14 additional days, the response had again dropped to levels similar to those before the second IVM injection. A third 10 mg/kg IVM injection again restored the maximal AMP induced rotation response when tested 24 hr later ( Figure 5B ). These data indicate that multiple cycles of IVM-induced silencing and recovery can be obtained within individual GluClab-expressing animals. A small but statistically significant level of residual AMPinduced rotation was observed at 14 days post-IVM injection ( Figure 5B ). To determine whether this incomplete extinction was due to IVM/AMP-induced cell death, we selected three representative mice that showed low but significant residual turning after 14 days, relative to that measured in their pretests ( Figure 5C , ''14 days''). The brains of these mice were collected and sectioned, and the density of NeuN + cells quantified by unbiased stereology, within 300 mm of the center of infection (as determined by costaining for GFP; Figure 1B ). The mirror-image of the contour used for counting was employed for quantification on the contralateral, uninfected side. No significant difference in the number of NeuN + cells per unit volume was found between the infected and the uninfected sides ( Figure 5D , p > 0.25), indicating that the IVM treatment did not cause detectable cell death.
Apomorphine Induces Rotation in the Same Direction as Amphetamine, in IVM-Injected GluClab-Expressing Mice The foregoing data indicated that unilateral expression of GluClab in the striatum causes a defect in dopaminergic neurotransmission, as assessed by AMP-induced rotation. In principle, this effect could be exerted by silencing of postsynaptic striatal neurons, presynaptic dopaminergic afferents (via retrograde transport of the injected virus to the substantia nigra), or by both. To determine whether the effect is primarily presynaptic, we tested the response of GluCl/IVM animals to apomorphine (APO), an agonist for postsynaptic dopamine D1 and D2 receptors. Unilateral denervation of dopaminergic afferents to the striatum causes postsynaptic receptor upregulation and therefore hypersensitivity to dopaminergic receptor agonists (Oberlander and Boissier, 1983; Ungerstedt, 1971) . Thus systemic administration of APO to such animals causes rotation in the direction contralateral to the lesioned side, opposite to the direction obtained with AMP. Therefore, if the effect of IVM-dependent GluCl-mediated silencing were exerted primarily through a presynaptic mechanism, APO should induce turning in the direction opposite to that induced by AMP. If, however, the effect is exerted postsynaptically (or both pre-and postsynaptically), then APO should induce rotation in the same direction as AMP, i.e., ipsilateral to the AAV2-injected side, similar to animals with unilateral kainic acidic induced lesions (Schwarcz et al., 1979) .
The results clearly indicated that systemic administration of APO (5 mg/kg) 24 hr after injection of 10 mg/kg IVM caused ipsilateral rotation in GluClab-expressing mice ( Figure 5E ; 21.5 ± 4.9, n = 5 animals, ANOVA; p < 0.01). The average rotation scores were lower in APOinjected than in the AMP-injected mice, consistent with previous reports that APO unlike AMP does not cause locomotor hyperactivity. Indeed, APO-treated animals moved more slowly during the 30 min test period ( Figure 5F ; p < 0.05, n = 5) and completed fewer 360 rotations. APO-induced rotations were not observed in animals injected with either AAV2-a or AAV2-b alone (n = 3 animals each) or in GluClab-expressing animals injected with APO prior to IVM administration ( Figure 5E ; À24 hr).
After 14 days, APO-induced circling dropped to levels barely significantly different from the AAV2-a-alone/ AAV2-b-alone control group ( Figure 5E, 14 days) . When animals were given a second 10 mg/kg IVM injection and tested with APO 24 hr later, the ipsilateral rotation score returned to levels similar to those obtained 24 hr after the initial IVM injection ( Figure 5E , ''24 hr after IVM react.''). Thus, the decay kinetics and reversibility seen with APO-induced rotation were similar to those observed with AMP. Taken together, these data support the idea that the GluCl/IVM system exerts its behavioral effect on dopaminergic transmission, at least in part, by silencing postsynaptic striatal neurons.
DISCUSSION
Here, we describe a method that allows reversible electrical silencing of genetically targeted CNS neurons in freely behaving mice, using a ligand that crosses the BBB. When AAV-mediated expression of GluClab occurs unilaterally in the striatum, systemic administration of IVM results in an AMP-or APO-dependent behavioral phenotype. Slice recording experiments indicate that this behavioral phenotype is correlated with IVM-dependent silencing of striatal neurons. To our knowledge, this is the first demonstration of reversible, genetic suppression of neuronal (E) Apomorphine-induced rotation test. APO (5 mg/kg) was delivered at the times indicated below the x axis, relative to injection of IVM (10 mg/kg; blue arrows). None of the AAV2-a-or AAV-b-injected animals showed rotation at any time point. *(AAV2-a+AAV2-b)-injected animals showed significant ipsilateral rotation 24 hr after both the first and second IVM injections. ANOVA for rotation scores with time (post-IVM injection) and GluClab subunits as parameters; p < 0.001. Post hoc unpaired t test (assuming unequal variance) showed significance for the individual time points; p < 0.01). (F) Comparison of distance moved during AMP-induced rotation test versus APO-induced rotation test. Animals were injected with 10 mg/kg IVM 24 hr before the rotation test. APO-treated animals moved significantly less distance than AMP-treated animals (p < 0.05; two tailed, unpaired t test assuming unequal variance). Error bars in (B)-(F) represent ±SEM. excitability resulting in a behavioral phenotype in mammals, triggered by systemic injection of a drug. The kinetics are well suited to many behavioral applications: onset within hours, a maximal effect that persists for several days, and reversal within two weeks.
In these experiments, silencing of striatal neurons by GluCl/IVM was inferred from the unilateral rotations produced in response to AMP. We chose this behavioral assay to obtain proof-of-principle data for the GluCl/IVM system in vivo, because the striatum provides a large target for stereotaxic injections, and because AMP-induced rotations are highly sensitive to unilateral striatal lesions or dopaminergic denervation (Anden et al., 1966; Schwarcz et al., 1979) . AMP was used for the in vivo experiments to elevate firing of the striatal medium spiny neurons, which normally fire at rather low rates (Berke et al., 2004) . Because the striatal slice preparations do not contain nigral dopaminergic neurons, injection of depolarizing current was employed to elevate firing rates in medium spiny neurons. (This tactic was not necessary to observe the effect of IVM on interneurons, which exhibit a higher level of spontaneous spiking than do MSNs, in slices.) The in vivo and slice experiments produced complementary results indicating that spiking was effectively silenced by IVM exposure in neurons from animals that expressed GluClab in the striatum. In addition, stereological counting indicated that the behavioral effect of AMP in GluCl/IVM mice is not due to striatal cell killing. Finally, the APO data argue that the behavioral phenotype is not due to retrograde silencing or killing of nigral dopaminergic afferents. Taken together, these data support the idea that the behavioral effects of AMP in GluCl/IVM mice indeed reflect silencing of striatal neurons.
Kinetics of IVM-Dependent Silencing by GluCl/IVM
The relatively slow (4-6 hr at 10 mg/kg) onset of IVM effects in vivo likely reflects its pharmacokinetics. Bath application of IVM to acute striatal slice cultures from GluCl/IVM-expressing animals showed repression of neuronal firing within minutes. Therefore, it is likely that faster onset kinetics, if desired, could be achieved by ICV administration of IVM. The persistence of IVM effects over several days could be advantageous in experiments where ongoing silencing is required during extended behavioral tasks. Nevertheless, the prolonged decay of IVM effects in vivo may prove problematic in some applications. Such slow recovery kinetics likely reflect the combined influence of both ligand clearance/metabolism and the slow dissociation of IVM from GluClab or slow turnover of GluCl subunits. Previous observations have indicated that it can take up to 8 hr for dissociated hippocampal neurons to recover from IVM-dependent silencing , and we did not observe recovery from silencing during the time that it was possible to record from neurons in our slice preparations. Therefore, other systems for neuronal silencing may be preferable where more rapidly reversible effects are required (Tan et al., 2006) .
IVM Is Well-Tolerated at the Cellular and Organismal Levels at Concentrations Required for
GluCl/IVM-Dependent Silencing IVM is routinely used for treatment of arthropod and nematode parasitic infections in mice and other mammals (Chabala et al., 1980; Conole et al., 2003; Geary, 2005) . The concentrations of IVM necessary to elicit a rapidonset and consistent silencing phenotype (5 mg/kg and 10 mg/kg) are higher than those used for antiparasitic treatment (0.2 mg/kg [Burdett et al., 1997] ). However, we did not observe any adverse effects on locomotor behavior and/or motor learning in wild-type mice at these doses ( Figure S1 ). Intraperitoneal injection of 20 mg/kg IVM and above did induce tremors and partial paralysis in some animals, consistent with IVM overdose (Roder and Stair, 1998) . Such adverse effects may arise because IVM is a GABA A receptor agonist at high concentrations (Dawson et al., 2000) . Mice deficient for the mdr1a P-glycoprotein are 100-fold more sensitive to IVM toxicity (Schinkel et al., 1996) ; therefore, IVM is likely cleared from the brain by this transporter. The 5-10 mg/kg IVM administered i.p. for silencing thus probably results in a much lower effective CSF concentration. Evidently, there exists a window of IVM concentrations in the CNS, allowing one to silence GluClab-expressing neurons without affecting nonexpressing neurons. Nevertheless, it would be advisable to test for the IVM sensitivity of each mouse strain before engaging in behavioral experiments (Davis et al., 1999) .
One concern was whether prolonged expression of the GluClab channel could be toxic to neurons. On the timescale of our experiments, even after repeated cycles of IVM-induced silencing, unbiased stereology revealed no difference in neuronal cell density between regions of high GluClab expression on the injected side of the striatum and the corresponding area on the contralateral uninjected side. Thus, it is unlikely that expression of GluClab, or short term IVM induced silencing, has any toxic effects on striatal neurons.
Levels of GluClab Expression Required for Silencing
In this study, we employed AAV2 virus-mediated transduction of striatal neurons to test IVM-dependent silencing, using an AMP-induced rotation assay. Interestingly, we observed a bimodal distribution in the strength of the phenotype. The group showing a strong rotation phenotype had an $3-fold higher infected volume of striatal tissue, as determined by quantitative anti-GFP immunohistochemistry, than the group showing a weak rotation phenotype. Moreover, the strength of the behavioral phenotype also correlated with the percentage of neurons that were strongly inhibited by IVM, when sampled by slice recording. These data suggest that the number of neurons infected in the striatum must be above a certain threshold, in order to elicit a strong rotation phenotype. However, other studies have found a more gradual correlation between the size of striatal lesions and the AMP-induced rotation phenotype (Kirik et al., 1998; Olds et al., 2006) . The reason for this difference is not clear but could reflect the fact that both the levels of GluClab expression, as well as the number of infected neurons, are likely to be lower in subthreshold animals (Figure 3) , whereas in lesion experiments only the number of killed cells is variable.
In animals showing a strong rotational phenotype, $80% of the neurons within the infected area expressed GluClab (assessed using anti-GFP antibody), and $50% of the cells showed a high level of expression of both subunits (assessed using CFP/YFP native fluorescence). Consistent with this, $70% of the neurons in slices from such animals exhibited reduced spiking in response to bath-applied IVM, and $70% of such neurons were fully inhibited. Furthermore, we observed a strong correlation between GluClab channel subunit expression levels and inhibition of firing by IVM, in individual neurons retrospectively identified by dye filling. Complete inhibition of spiking was observed in cells expressing GluClab at levels more than 15-fold lower than the highest levels detectable in the slices. Thus, while very high levels of GluClab expression can be achieved using the AAV2 expression system, efficient silencing of striatal neurons does not require maximal levels of expression.
The question arises as to whether cellular promoters, rather than the strong viral promoter (CMV) used in our experiments, would drive sufficient levels of GluCl subunit expression to achieve silencing. In ongoing experiments, we have obtained behavioral phenotypes in mice in which the GluCla subunit was expressed from a cellular promoter, using a BAC transgene, and the b subunit was provided by AAV2 injection (W. Haubensak and D.J.A., unpublished data). However, other experiments, using a different cellular promoter to express both subunits, have been less successful. In practice, the level of GluCl expression necessary to silence a given type of neuron will depend on the intrinsic strength of the chosen promoter, the number of copies and chromosomal integration site of the transgene, and the surface membrane area of the targeted neuron subtype. The uncertainties associated with this type of approach could be reduced by conditionally expressing GluCl from a strong constitutive promoter (such as CMV) and using cell-specific promoters to express Cre or FLP recombinase, thereby enabling GluCl expression in a specific pattern at high levels.
Extent of Reversibility of Silencing by GluCl/IVM
The GluCl/IVM silencing method is, in principle, not only inducible, but also reversible. In time-course experiments on animals each receiving a single injection of IVM and tested with AMP at a single time point, we observed a return to very low, nonsignificant levels of rotation by 4 to 5 days after the initial IVM injection ( Figure 4D ). These data suggest that GluCl/IVM-dependent silencing is fully reversible. However, in animals receiving multiple tests with AMP over several days, residual turning was observed even at 14 days after IVM injection ( Figures 5B and 5C ). It is unlikely that this small amount of residual turning is due to prolonged silencing of a portion of neurons because animals receiving a single AMP injection 14 days after IVM administration showed almost no detectable rotation ( Figure 4D ). The reason for this difference is currently unclear but could involve cumulative effects of multiple AMP injections or behavioral conditioning caused by directional bias during the repeated AMP-induced rotation tests. The reversibility of the system was confirmed by the fact that a second injection of IVM, two weeks after the first one, restored the phenotype to the levels observed after the initial injection, when tested with AMP 24 hr later.
A Combinatorial Strategy for Increased Specificity of Genetic Neuronal Silencing Genetically based neuronal silencing will be useful for the behavioral analysis of neuronal circuits defined by molecular markers. The requirement for two subunits to encode a functional GluClab receptor is an advantageous feature of this system. Global analyses of gene expression in the CNS (Gong et al., 2003; Heintz, 2004; Lein et al., 2007) have indicated that, while there are many genes that define neuronal subsets in specific areas of the brain, most such genes are expressed in several other brain areas and/or in other regions of the body. Probably, very few promoters are exclusively expressed in a single neuronal subtype within a single brain region (Gong et al., 2003; Heintz, 2004; Zhang et al., 2001) . The need for two GluCl subunits permits, in principle, a refinement of cell-type or regional silencing in the brain by using two different promoters, with partially overlapping specificities, to drive expression of each subunit. Such an approach has the advantage that all mice will express the two subunits in a reproducible pattern, minimizing animal-to-animal variability in the extent of silencing. However, it requires identification of promoter combinations with the requisite limited overlap.
A combinatorial approach can also be achieved by stereotaxic injection of a virus encoding one GluCl subunit into the brain region of interest in a transgenic mouse in which the other subunit is expressed under the control of a specific promoter. In this way, only neurons expressing the specific promoter within the injected region will be silenced. Although this method suffers from more inherent variability, due to the imprecision of injections, it has the advantage that a single mouse line can be exploited to silence neurons in whichever brain regions express the complementary GluCl subunit transgene. Expression of the two GluCl subunits using two viruses containing cellspecific promoters, rather than the constitutive CMV promoter used here, is also possible. This strategy can also be applied to experimental organisms in which routine transgenesis is difficult, such as nonhuman primates. While combinatorial approaches are not unique to the GluCl system Karpova et al., 2005; Tan et al., 2006) , their application will likely become increasingly necessary as more specific manipulations of neuronal subsets are required.
The GluCl/IVM method is a promising new tool for studying the behavioral effects of inducibly and transiently silencing molecularly defined circuits in the mammalian brain. It adds to the growing repertoire of techniques for genetically encoded inhibitors of neuronal activity or neurotransmission (reviewed in Callaway [2005] ). While each of these methods has particular shortcomings, their application in combination should permit rigorous tests of causal relationships among the firing of individual cell types, activity of neuronal circuits, and behavior.
EXPERIMENTAL PROCEDURES
Constructs and Virus Production
The woodchuck hepatitis posttranscriptional regulatory element (WPRE) was inserted between the ClaI and the XhoI restriction site of the Multiple Cloning sequence (MCS) of the pAAV-MCS vector of the AAV Helper-Free System (Stratagene 240071). The synthetically generated sequences for optGluCla-CFP or optGluClbY182F-YFP (Slimko and Lester, 2003) were then cloned into the ClaI site to produce pAAV-GluCla and pAAV-GluClb, respectively. Both constructs were commercially packaged and serotyped with the AAV2 capsid protein by Virapure, Inc., using the AAV Helper-Free System (Stratagene 240071).
Animal Maintenance C57B6 male mice bred at the California Institute of Technology (founders originally purchased from Charles River) were housed with ad libitum access to food and water. The temperature was maintained at 23 C and lights were set to 13 hr day, 11 hr night cycle (day cycle starting at 10 p.m.). Mice were singly housed at least 24 hr prior to surgery. Singly housed mice were given a red plastic house for environmental enrichment.
Stereotaxic Surgery
Stereotaxic injections were performed using standard procedures. Details are available in Supplemental Experimental Procedures.
Ivermectin and Vehicle Intraperitoneal Injections
A 1% sterile solution of Ivermectin (Phoenectin, AmTech) was diluted with sterile propylene glycol to the appropriate dilution and injected i.p. at 1ml/g animal body weight. Vehicle-injected animals received injections of 1ml/g animal body weight of propylene glycol without IVM.
AMP and APO-Induced Rotation Test AMP, d-Amphetamine sulfate (Sigma A-5880), or APO, R-(À)-Apomorphine hydrochloride hemihydrate (Sigma A4393-1G) were dissolved in sterile PBS at 10 mg/ml and diluted to 1 mg/ml in sterile saline for i.p. injections. Mice received i.p. injections of 5 mg/kg of either AMP or APO in their home cage and were placed into a box in the openfield setup within 2-5 min. The open field setup was made of four open acrylic boxes, each 55 3 55 cm wide, with 15 cm high walls. The movement of up to four mice was recorded with a top-mounted camera and captured with the Mediacruise program (Canopus). The movie files were then analyzed using the Ethovision software (Noldus). Traces for each mouse were recorded for 30 min, starting 10 min after the mouse had been placed into the open field setup. Rotation scores (ipsilateral circles per 10 min) were calculated by subtracting contralateral rotations from ipsilateral rotations and dividing the result by the total distance moved.
Histology optGluCla-CFP, optGluClbY182F-YFP, and NeuN antigen were visualized on 120 mm vibratome section slices or 30 mm frozen sections by antibody staining against GFP (Molecular Probes A11122) and NeuN (Chemicon MAB377). See Supplemental Experimental Procedures for a detailed description of the procedure. For visualization of native YFP or CFP, a mock-staining procedure (no addition of antibody) was performed in order to reduce autofluorescence.
Cell Quantification GFP staining was performed on 120 mm floating sections. Using the Stereo Investigator software (Microbrightfield, Inc) the area of the most intense staining was contoured, approximately circumscribing a radius of 300 mm from the injection site in the right striatum. The contour was saved, and a mirror image of the contour was created on the left side of the striatum (control side). A random raster was created by the software and cells were counted in three dimensions, excluding the top and bottom 10 mm of each section. Movement along the raster was controlled by the software using a motorized stage. The counts were extrapolated for each sample (three sections per mouse) and had an estimated coefficient of error (Scheaffer) <0.05.
Volume Estimation
The area of red anti-GFP staining was contoured on each section using the Stereo Investigator software. The surface area of the contour was automatically calculated, multiplied by the 120 mm section thickness, and added up over all sections that showed staining for the GFP antigen.
Slice Preparation for Electrophysiology
Striatal slices were prepared as described (Ye et al., 2006) , with minor modifications. See Supplemental Experimental Procedures for details.
Electrophysiological Recordings
A single slice was transferred into the 0.8 ml recording chamber. Throughout the experiments, the bath was continually perfused with ACSF (1.5-2.0 ml/min). Cells were visualized with an upright microscope (BX 50WI, Olympus) and near-infrared illumination. The patch electrodes had a resistance of 5-8 MU, when filled with pipette solution: 135 mM Potassium gluconate, 5 mM EGTA, 0.5 mM CaCl 2 , 2 mM MgCl 2 , 10 mM HEPES, 2 mM Mg-ATP, and 0.1 mM GTP. The pH of the pipette solution was adjusted to 7.2 with tris-base and the osmolarity to 280-300 mOsm with sucrose. The action potential firing was recorded, in the mode of whole-cell current clamp or loose-patch cell-attached voltage clamp, with MultiClamp 700B amplifiers (Axon Instruments), a Digidata 1200A A/D converter, and pCLAMP 9.2 software (Axon Instruments). Data were sampled at 10 kHz and filtered at 2 kHz. The junction potential between the patch pipette and the bath solution was nulled just before gigaseal formation. Recordings were performed at 32 C.
Quantification of CFP and YFP Fluorescence following Electrophysiology
For retrospective quantification of CFP and YFP fluorescence, Alexa Fluor 647 dextran (Invitrogen Inc., catalog number, D-22914) was dissolved in intrapipette solution (0.02%), backfilled in the recording electrode, and injected into the recorded neuron during whole-cell patch clamp recording. See Supplemental Experimental Procedures for details on fluorescence quantification.
Supplemental Data
The Supplemental Data for this article can be found online at http:// www.neuron.org/cgi/content/full/54/1/35/DC1/.
